Compositions and methods of treating liver disease
Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method may comprise the step of administering a composition comprising obeticholic acid to an individual in need thereof.
1. A method of treating or reducing the occurrence of a steatohepatitis disorder selected from NASH, parenteral nutrition associated liver disease (PNALD), and a genetic liver disease, comprising the step of administering a composition comprising obeticholic acid and Fibroblast Growth Factor 19 (“FGF19”) to an individual in need thereof.
2. The method of claim 1 , wherein said composition is administered in an amount sufficient to reduce the occurrence of liver cell fibrosis.
3. The method of claim 1 wherein said composition is administered prior to, following, or during administration of parenteral nutrition to said individual in need thereof.
4. The method of claim 1 wherein said composition comprises a buffer.
5. The method of claim 1 wherein said composition a carrier.
6. The method of claim 1 wherein said composition is administered parenterally or intravenously.
7. A composition comprising
a. total parenteral nutrition (TPN) or peripheral parenteral nutrition (PPN);
b. Fibroblast Growth Factor 19 (“FGF19”); and
c. obeticholic acid.
8. An article of manufacture comprising a container, a composition of claim 7 in a dosage form, and instructions for administering said dosage form to an individual diagnosed or suspected of having or developing PNALD.